Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.60 1.49% 41.00 40.10 41.00 40.80 40.00 40.00 60,040 16:35:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 11.8 187

Ekf Diagnostics Share Discussion Threads

Showing 3476 to 3498 of 4475 messages
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older
DateSubjectAuthorDiscuss
19/5/2021
08:01
I think the private sector partner is Avacta AVCT who have developed the gold standard LFT test but are short of capacity for anticipated demand. They are making equivalent reciprocal noises about gearing up production capacity with partners. AVCT being an UK company and having a great test are likely to get a big chunk of any UK Govt contracts going forward.
tigletpiglet
19/5/2021
07:56
I am surprised that there has not been more comment on the extent of the management changes. Change is inevitable, but to replace both the CEO and the CFO within the space of 12 months (plus a long serving non-exec)is pretty unusual. It also suggests that management control may be centred in the US - something that I have asked the company about this morning. Other than that, I agree that the AGM statement is very positive.
james188
19/5/2021
07:38
That whole AGM Statement is glowing with ambition, confidence and vision. The short term catalyst will be expansion of their services with Amazon but we have a strategy from them that clearly shows we are on the next leg of our "accelerated growth" in the core business Ain't no stopping us :-) hTTps://twitter.com/MGinvestor/status/1394901847798915075?s=20 @mginvestor
mginvestor
19/5/2021
07:35
Todays' news represents even more than I was wishing and hoping for! And see's EKF at a very significant inflection point in terms of further growth, increasing earnings and on the cusp of realising a raft of exciting opportunities.....fantastic news.....and a fantastic growth plan!
wan
19/5/2021
07:22
We are already in discussions with our private sector partner, with whom we have a recently signed, multi-million dollar global supply contract, regarding the expansion of our support beyond their world-wide COVID-19 testing programme for their staff, to supporting a much broader commercial testing capacity to cover other areas of infectious disease, chronic disease and general health and wellness. Sounds great! Anything with ‘that’ company isnt going to be small beer!
mysteronz
19/5/2021
07:13
Excellent news, couldn't ask for more, the runway is extensive!
hastings
19/5/2021
07:10
Shanklin, this has not been an ordinary year. My point was the share price movement indicated a statement was coming and the way EKF has flexed and grown in the last year would make no statement an odd decision. Also being so particualrly invited to the meeting suggested to me anyway they had somehting to tell. And wow they have!
faz
19/5/2021
07:08
Lovely stuff in the AGM statement today: "the Board is now confident that trading for the full year will be comfortably ahead of already upgraded management expectations" Even better are the various plans going forward, which look transformative. It's also great (from EKF's perspective anyway) to hear that its COVID-19 business will "continue for many years to come".
rivaldo
19/5/2021
07:06
Very happy to be wrong about the provision of a TS today :-)))))))))))))
shanklin
18/5/2021
18:04
Could be wishful thinking imo
tongosti
18/5/2021
16:12
What AGM statement? There hasn't been an update on trading on AGM day in the last two years. Will this year be different for some reason?
shanklin
18/5/2021
14:29
Amazing how it happens every time just before information release dates - up 5% today. I bought more yesterday morning and look forward to the AGM statement; I've got my seat booked.
faz
18/5/2021
12:56
Surely you mean food for ramping old chap
tongosti
18/5/2021
11:34
And I also find myself asking (myself!).....what is it that is making it confidentially restricted as to who EKF's private sector partner is? Food for thought!
wan
18/5/2021
11:21
quick Tong, declare that you're long EKF from 60p (60.2p after cost we know how precise you are...) today cos Mr Market gave you free shares for the ride. Wouldn't want anyone dare saying you're a blagger Quick mate, it's about to explode
mg1982
18/5/2021
11:20
Importantly, it should also be noted how well telehealth and digital health offerings dovetails with near patient testing/at-home testing, and self-collection tests etc.
wan
18/5/2021
10:30
Back to EKF's core diagnostic business - Some investors may have noted that PerkinElmer is to buy Immunodiagnostic Systems (IDH) for a significant premium to its volume weighted average share price. Making it PerkinElmer's 3rd acquisition this year, and further demonstrates the interest and likelihood of further M&A in our sector. I am expecting that interest to also extend to and include near patient testing, given that the pandemic has also opened many companies eyes to the possibility of using point of care testing (POCT), as well as at-home testing and self-collection for other disease states, for the valuable role that can play in healthcare in general, even where POCT wasn't a part of their existing portfolio's. During a recent 360DX roundtable on the post-vaccine testing landscape, Nathan Ledeboer, medical director of clinical microbiology and molecular diagnostics at Froedtert Hospital and the Medical College of Wisconsin, said that he believed that the shift to at-home testing and self-collection "precipitated as a result of COVID is going to fundamentally reshape the diagnostics industry and healthcare in general," and added that he thought this reshaping would prove to be one of the major impacts of the pandemic - shorturl.at/msBGJ With a senior VP at Laboratory Corporation of America, also recently saying that COVID-19 was driving a "paradigm shift" toward home testing. So, with exposure to laboratory diagnostics market, rapid testing and POC testing markets, and a firm footing established in self-collection (and potentially at-home testing), not to mention having the expertise and experience in navigating the tough regulatory hurdles to obtain the necessary approvals, EKF is very well placed indeed to flourish today and 'beyond' the pandemic!
wan
18/5/2021
10:21
All good stuff! No price announced yet. If it follows the RNLX model it will be over-subscribed with a healthy premium. CD
cambridgedon
18/5/2021
10:10
Market at 66 - excitement in the air?
tongosti
18/5/2021
08:55
Morning Rivaldo,Thats exactly what I have just done and as you said blown someone's mind at 8.30 in the morning.Speed is of the essence with this one so if anyone gets any more info would be great to share GLA
riddlerone
18/5/2021
08:48
Yes indeed, Trellus is yet another example and result of the managements foresight and efforts in providing returns to shareholders via the dividend in specie and IPO route, which the management see as providing shareholders with a far greater reward than just paying a cash dividend. So, it's worth bearing in mind that EKF are aiming to do one investment and one floatation per year, and are thus hoping to do another spin off next year (technology investment yet to be revealed/decided, but one would obviously expect an announcement on such a decision/investment to be well in advance of a spin-off for next year). With new technologies and spin-offs firmly in mind, and food for thought, I do wonder what might be in store for Kantaro Biosciences - We ensure that high-quality diagnostics tests for critical health challenges are accessible. Kantaro is a joint venture of the Mount Sinai Health System and RenalytixAI (NASDAQ:RNLX). We specialize in the rapid scale up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to the market. Together with our partners, we provide academically rigorous, validated and results-driven diagnostics with the goal to advance the well-being of people, communities and society. hTTps://kantarobio.com/about-us/
wan
18/5/2021
08:44
It appears that as a Qualifying Shareholder of Trellus via my dividend in specie, I can apply for additional IPO shares. However, as the shares are presumably held at this stage beneficially for me and likely almost all PIs by our stockbrokers, I now have to contact my stockbroker to obtain application instructions for me and then submit that application. Which probably means (knowing most brokers) that they'll be completely unaware of any of this and will have to look into it and scramble to manage the process in time. Can someone confirm that I've understood this correctly please?!
rivaldo
18/5/2021
07:24
Intention to Float on AIM Proposed placing, subscription and restricted offer LONDON, UK. AND NEW YORK, U.S. (18 May 2021). Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, confirms its intention to seek admission of its issued share capital, as enlarged by a proposed placing, subscription and a restricted offer (together, the "Fundraising"), to trading on AIM ("Admission"). Trellus Health is pleased to announce that it has received strong indications of demand for the placing of new ordinary shares in the capital of the Company ("Ordinary Shares" or "Trellus Shares") and] also confirms the launch of a restricted offer, to be made available for a limited period only to qualifying Trellus Health shareholders. Further information on the Restricted Offer is contained below. This release is being linked to the EKF ticker for information purposes only.
masurenguy
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220928 16:48:41